Press Releases
Washington, D.C.—Yesterday, Congressman Tom Marino (PA-10), introduced H.R. 4540, legislation requiring the repayment of taxpayer dollars used in sexual harassment settlements against a Member of Congress, including interest. The bill would also:
Washington, D.C.—Today, Congressman Tom Marino (PA-10) and Congressman Lou Barletta (PA-11) introduced H.R. 4493, Eric’s Law, named in honor of fallen Bureau of Prisons Correctional Officer Eric Williams.
Washington, D.C. - Today, Congressman Tom Marino (PA-10), introduced H.R. 4458, legislation to ensure that taxpayer funds cannot be used to pay settlements resulting from sexual harassment by a Member of Congress. The bill also requires that the Ethics Committee consider the expulsion of a Congressman or Senator if they commit an act of sexual harassment.
Washington, D.C –Today, Congressman Tom Marino (PA-10) voted in favor of H.R.1, the Tax Cuts & Jobs Act which passed the House of Representatives by a vote of 227-205.
Washington D.C. - Congressman Tom Marino (PA-10) issued the following statement after President Donald Trump announced the opioid crisis is a national public health emergency:
ICYMI: Rep. Marino Op-Ed: Truth is the Key to Solving the Opioid Crisis
The Hill
October 25, 2017
““What is truth?” was Pontius Pilate’s famous question to Jesus. In our nation’s capital and the media, the answer seems to be “whatever the Washington Post says it is.”
ICYMI: Implausible Rep. Tom Marino led a Bipartisan Conspiracy to Worsen Drug Addiction Crisis
Bipartisan Drug Cartel?
The Wall Street Journal
The Editorial Board
October 24, 2017
Washington, D.C.— Congressman Tom Marino (R-PA-10) issued the following statement after requesting that President Donald Trump withdraw his name from consideration to lead the Office of National Drug Control Policy (ONDCP):
“Today I informed President Donald Trump of my intent to withdraw my name from any further consideration to lead ONDCP.
Washington, D.C.—Tomorrow at 1:00 p.m. Congressman Tom Marino (PA-10) will hold a hearing on anticompetitive behavior and the health care marketplace.
Washington, D.C.--Today, the U.S. Food and Drug Administration (FDA) held a public meeting to solicit input in areas where the FDA’s rules are being used in ways that create obstacles and delays. FDA Commissioner Scott Gottlieb, M.D., has shown a commitment to ensuring that generic manufacturers have access to promote competition.